Trade Blueprint Medicines Corporation - BPMC CFD

Add to favourite

88.82

0.63%

View detailed chart

To be able to trade stocks like this, create an account and apply for a stock listing.

Create Account

Summary
Historical Data
Events
Income Statement
Balance Sheet
Cash Flow

Trading сonditions

Spread

0.23

Long position overnight fee

-0.026179%

Short position overnight fee

0.003957%

Overnight fee time

21:00 (UTC)

Min traded quantity

Currency

USD

Margin

Stock exchange

United States of America

Commission on trade

*Information provided by Capital.com

Blueprint Medicines Corp ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats

Prev. Close*	88.26
Open*	87.43
1-Year Change*	81.84%
Day's Range*	86.3 - 91.19
52 wk Range	37.82-94.00
Average Volume (10 days)	739.02K
Average Volume (3 months)	18.26M
Market Cap	4.84B
P/E Ratio	-100.00K
Shares Outstanding	60.79M
Revenue	216.20M
EPS	-9.20
Dividend (Yield %)	N/A
Beta	0.63
Next Earnings Date	Feb 14, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Apr 18, 2024	88.82	2.15	2.48%	86.67	91.45	85.89
Apr 17, 2024	88.26	3.30	3.88%	84.96	89.43	84.56
Apr 16, 2024	85.39	1.37	1.63%	84.02	87.85	83.82
Apr 15, 2024	84.53	-1.20	-1.40%	85.73	87.61	84.05
Apr 12, 2024	86.78	-5.15	-5.60%	91.93	92.53	86.69
Apr 11, 2024	92.12	1.98	2.20%	90.14	92.49	89.95
Apr 10, 2024	89.88	3.92	4.56%	85.96	90.41	81.99
Apr 9, 2024	92.06	0.21	0.23%	91.85	93.69	90.15
Apr 8, 2024	91.47	2.23	2.50%	89.24	92.33	89.24
Apr 5, 2024	91.45	2.66	3.00%	88.79	91.54	87.52
Apr 4, 2024	90.59	0.14	0.15%	90.45	92.84	90.21
Apr 3, 2024	88.07	-1.65	-1.84%	89.72	93.17	88.07
Apr 2, 2024	91.41	-1.65	-1.77%	93.06	93.61	89.98
Apr 1, 2024	96.33	3.71	4.01%	92.62	96.93	92.62
Mar 28, 2024	94.67	0.29	0.31%	94.38	95.66	90.71
Mar 27, 2024	94.19	5.14	5.77%	89.05	94.75	88.71
Mar 26, 2024	89.50	1.36	1.54%	88.14	92.08	87.94
Mar 25, 2024	88.02	1.09	1.25%	86.93	89.38	86.83
Mar 22, 2024	86.92	-3.36	-3.72%	90.28	90.28	86.69
Mar 21, 2024	89.78	1.59	1.80%	88.19	91.26	88.19

Blueprint Medicines Corporation Events

Time (UTC)	Country	Event
Thursday, April 25, 2024
Time (UTC) 14:00	Country US	Event Blueprint Medicines Corp To Discuss Emerging Opportunities for Mast Cell-Targeted Therapeutics Call Blueprint Medicines Corp To Discuss Emerging Opportunities for Mast Cell-Targeted Therapeutics Call Forecast - Previous -
Thursday, May 2, 2024
Time (UTC) 12:30	Country US	Event Q1 2024 Blueprint Medicines Corp Earnings Release Q1 2024 Blueprint Medicines Corp Earnings Release Forecast - Previous -
Thursday, June 20, 2024
Time (UTC) 19:30	Country US	Event Blueprint Medicines Corp Annual Shareholders Meeting Blueprint Medicines Corp Annual Shareholders Meeting Forecast - Previous -
Wednesday, July 31, 2024
Time (UTC) 12:30	Country US	Event Q2 2024 Blueprint Medicines Corp Earnings Release Q2 2024 Blueprint Medicines Corp Earnings Release Forecast - Previous -

View all events

Annual
Quarterly

	2022	2021	2020	2019	2018
Total revenue	204.036	180.08	793.735	66.512	44.521
Revenue	204.036	180.08	793.735	66.512	44.521
Total Operating Expense	741.554	822.061	485.028	427.838	291.549
Selling/General/Admin. Expenses, Total	237.374	195.293	157.743	96.388	47.928
Research & Development	477.419	601.033	326.86	331.45	243.621
Operating Income	-537.518	-641.981	308.707	-361.326	-247.028
Interest Income (Expense), Net Non-Operating	-16.767	2.386	6.599	13.732	-0.073
Other, Net	2.004	-1.489	-0.366	-0.1	10.459
Net Income Before Taxes	-552.281	-641.084	314.94	-347.694	-236.642
Net Income After Taxes	-557.517	-644.085	313.882	-347.694	-236.642
Net Income Before Extra. Items	-557.517	-644.085	313.882	-347.694	-236.642
Net Income	-557.517	-644.085	313.882	-347.694	-236.642
Total Adjustments to Net Income					0
Income Available to Common Excl. Extra. Items	-557.517	-644.085	313.882	-347.694	-236.642
Income Available to Common Incl. Extra. Items	-557.517	-644.085	313.882	-347.694	-236.642
Diluted Net Income	-557.517	-644.085	313.882	-347.694	-236.642
Diluted Weighted Average Shares	59.642	58.518	56.168	47.829	43.867
Diluted EPS Excluding Extraordinary Items	-9.34772	-11.0066	5.58827	-7.26952	-5.39453
Diluted Normalized EPS	-9.34772	-11.0066	5.58827	-7.26952	-5.39453
Cost of Revenue, Total	17.813	17.934	0.425
Gross Profit	186.223	162.146	793.31
Other Operating Expenses, Total	8.948	7.801

	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022
Total revenue	56.566	57.57	63.287	38.781	65.977
Revenue	56.566	57.57	63.287	38.781	65.977
Cost of Revenue, Total	2.782	2.323	3.175	4.848	3
Gross Profit	53.784	55.247	60.112	33.933	62.977
Total Operating Expense	185.546	185.551	187.494	188.58	190.254
Selling/General/Admin. Expenses, Total	70.741	71.931	70.95	64.02	57.608
Research & Development	110.252	110.063	112.073	117.84	127.981
Operating Income	-128.98	-127.981	-124.207	-149.799	-124.277
Interest Income (Expense), Net Non-Operating	-3.808	-3.996	-5.819	-9.24	-8.396
Other, Net	-0.728	-0.626	0.986	1.429	0.396
Net Income Before Taxes	-133.516	-132.603	-129.04	-157.61	-132.277
Net Income After Taxes	-133.713	-132.793	-129.56	-158.646	-133.163
Net Income Before Extra. Items	-133.713	-132.793	-129.56	-158.646	-133.163
Net Income	-133.713	-132.793	-129.56	-158.646	-133.163
Income Available to Common Excl. Extra. Items	-133.713	-132.793	-129.56	-158.646	-133.163
Income Available to Common Incl. Extra. Items	-133.713	-132.793	-129.56	-158.646	-133.163
Diluted Net Income	-133.713	-132.793	-129.56	-158.646	-133.163
Diluted Weighted Average Shares	60.688	60.516	60.126	59.876	59.758
Diluted EPS Excluding Extraordinary Items	-2.20329	-2.19435	-2.15481	-2.64958	-2.22837
Dividends per Share - Common Stock Primary Issue	0	0	0		0
Diluted Normalized EPS	-2.20329	-2.19435	-2.15481	-2.64958	-2.22837
Other Operating Expenses, Total	1.771	1.234	1.296	1.872	1.665

Annual
Quarterly

	2022	2021	2020	2019	2018
Total Current Assets	1046.65	554.025	927.759	516.786	499.787
Cash and Short Term Investments	944.992	477.114	871.849	483.554	494.012
Cash & Equivalents	119.709	209.948	684.636	113.938	68.064
Short Term Investments	825.283	267.166	187.213	369.616	425.948
Total Receivables, Net	36.938	37.03	25.309	23.412	0.215
Accounts Receivable - Trade, Net	36.938	37.03	25.309	23.412	0.215
Prepaid Expenses	35.024	18.064	22.02	9.82	5.56
Total Assets	1349.9	1252.22	1718.39	707.694	540.124
Property/Plant/Equipment, Total - Net	115.198	120.862	101.668	111.114	29.627
Property/Plant/Equipment, Total - Gross	146.48	146.28	121.399	124.798	38.282
Accumulated Depreciation, Total	-31.282	-25.418	-19.731	-13.684	-8.655
Long Term Investments	133.48	557.529	677.873	64.406	0
Other Long Term Assets, Total	54.573	19.809	11.093	15.388	10.71
Total Current Liabilities	183.234	149.765	130.802	106.482	60.323
Accounts Payable	2.729	8.333	4.37	4.793	3.298
Accrued Expenses	141.702	129.922	113.873	95.529	51.711
Notes Payable/Short Term Debt	0	0	0	0	0
Current Port. of LT Debt/Capital Leases	16.851
Other Current Liabilities, Total	21.952	11.51	12.559	6.16	5.314
Total Liabilities	835.225	281.49	248.305	243.335	121.115
Total Long Term Debt	122.232	0	0	0	0
Long Term Debt	122.232
Other Liabilities, Total	529.759	131.725	117.503	136.853	60.792
Total Equity	514.677	970.735	1470.09	464.359	419.009
Common Stock	0.06	0.059	0.058	0.049	0.044
Additional Paid-In Capital	2358.02	2250.25	2106.6	1412.08	1016.69
Retained Earnings (Accumulated Deficit)	-1832.96	-1275.44	-631.356	-945.238	-597.545
Other Equity, Total	-10.443	-4.133	-5.214	-2.535	-0.18
Total Liabilities & Shareholders’ Equity	1349.9	1252.22	1718.39	707.694	540.124
Total Common Shares Outstanding	59.9589	59.1411	57.7935	49.2722	44.037
Preferred Stock - Non Redeemable, Net	0	0		0
Total Inventory	29.697	21.817	8.581

	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022
Total Current Assets	808.172	811.335	900.344	1046.65	1227.67
Cash and Short Term Investments	712.984	722.634	822.161	944.992	1136.96
Cash & Equivalents	55.972	75.527	169.724	119.709	291.43
Short Term Investments	657.012	647.107	652.437	825.283	845.535
Total Receivables, Net	41.254	38.267	31.303	36.938	21.915
Accounts Receivable - Trade, Net	41.254	38.267	31.303	36.938	21.915
Total Inventory	16.457	17.016	17.521	29.697	35.253
Prepaid Expenses	37.477	33.418	29.359	35.024	33.532
Total Assets	1105.3	1106.44	1220.37	1349.9	1458.39
Property/Plant/Equipment, Total - Net	115.84	114.486	113.409	115.198	117.371
Property/Plant/Equipment, Total - Gross				146.48
Accumulated Depreciation, Total				-31.282
Long Term Investments	114.242	113.932	139.15	133.48	55.675
Other Long Term Assets, Total	67.045	66.692	67.467	54.573	57.681
Total Current Liabilities	197.384	169.028	172.684	183.234	175.51
Accounts Payable	6.963	6.979	10.563	2.729	4.233
Accrued Expenses	122.053	112.454	119.622	141.702	130.879
Notes Payable/Short Term Debt	0	0	0	0	0
Other Current Liabilities, Total	38.147	31.738	25.117	21.952	25.108
Total Liabilities	902.688	795.315	806.072	835.225	818.085
Total Long Term Debt	208.157	122.146	122.13	122.232	123.06
Other Liabilities, Total	497.147	504.141	511.258	529.759	519.515
Total Equity	202.611	311.13	414.298	514.677	640.307
Common Stock	0.061	0.061	0.06	0.06	0.06
Additional Paid-In Capital	2434.26	2410.6	2381.36	2358.02	2329.39
Retained Earnings (Accumulated Deficit)	-2229.02	-2095.31	-1962.52	-1832.96	-1674.31
Other Equity, Total	-2.683	-4.221	-4.602	-10.443	-14.826
Total Liabilities & Shareholders’ Equity	1105.3	1106.44	1220.37	1349.9	1458.39
Total Common Shares Outstanding	60.7407	60.6383	60.4163	59.9589	59.8085
Preferred Stock - Non Redeemable, Net	0	0	0	0	0
Current Port. of LT Debt/Capital Leases	30.221	17.857	17.382	16.851	15.29
Long Term Debt	208.157	122.146	122.13	122.232	123.06

Annual
Quarterly

	2022	2021	2020	2019	2018
Net income/Starting Line	-557.517	-644.085	313.882	-347.694	-236.642
Cash From Operating Activities	-502.277	-298.653	387.035	-278.015	-175.009
Cash From Operating Activities	11.735	6.479	6.559	5.259	4.246
Non-Cash Items	97.274	362.633	82.212	54.695	26.147
Cash Interest Paid	9.814		0	0.005	0.267
Changes in Working Capital	-53.769	-23.68	-15.618	9.725	31.24
Cash From Investing Activities	-149.541	-225.86	-434.249	-16.466	-161.088
Capital Expenditures	-8.919	-3.089	-3.159	-14.013	-12.677
Other Investing Cash Flow Items, Total	-140.622	-222.771	-431.09	-2.453	-148.411
Cash From Financing Activities	561.81	50.716	617.759	340.638	4.454
Financing Cash Flow Items	415.828	0	0	-0.4	-0.281
Issuance (Retirement) of Stock, Net	8.196	50.716	617.759	341.038	6.425
Issuance (Retirement) of Debt, Net	137.786		0	0	-1.69
Net Change in Cash	-90.215	-474.685	570.2	46.175	-331.643
Cash Taxes Paid	6.505	0.694	0.778	0.185
Foreign Exchange Effects	-0.207	-0.888	-0.345	0.018

	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022
Net income/Starting Line	-129.56	-557.517	-398.871	-265.709	-105.999
Cash From Operating Activities	-122.961	-502.277	-380.872	-250.982	-132.726
Cash From Operating Activities	3.684	11.735	4.719	3.098	1.628
Non-Cash Items	29.336	97.274	60.743	53.403	26.249
Cash Taxes Paid	0.311	6.505	4.018	0.771	0.169
Changes in Working Capital	-26.421	-53.769	-47.463	-41.774	-54.604
Cash From Investing Activities	172.791	-149.541	-96.258	35.977	-41.09
Capital Expenditures	-2.584	-8.919	-7.438	-3.709	-1.153
Other Investing Cash Flow Items, Total	175.375	-140.622	-88.82	39.686	-39.937
Cash From Financing Activities	0	561.81	559.319	178.762	1.264
Issuance (Retirement) of Stock, Net	0	8.196	5.686	3.762	1.264
Foreign Exchange Effects	0.197	-0.207	-0.685	-0.306	-0.197
Net Change in Cash	50.027	-90.215	81.504	-36.549	-172.749
Financing Cash Flow Items		415.828	415.836	175
Cash Interest Paid	7.084	9.814	2.956
Issuance (Retirement) of Debt, Net		137.786	137.797

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

1:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Blueprint Medicines Corporation Company profile

About Blueprint Medicines Corp

Blueprint Medicines Corporation is a global precision therapy company that is inventing medicines for people with cancer and blood disorders. The Company delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and GAVRETO (pralsetinib) to patients in the United States and Europe, and it is globally advancing multiple programs for systemic mastocytosis (SM), lung cancer and other genomically defined cancers, and cancer immunotherapy. Its pipelines also include BLU-263 (KIT), AYVAKIT (avapritinib) (PDGFRA), BLU-701 (EGFR), BLU-945 (EGFR), BLU-451 (EGFR exon 20 insertions), BLU-222 (CDK2) and BLU-852 (MAP4K1). It is developing and commercializing avapritinib for the treatment of advanced SM, and developing avapritinib for the treatment of non-advanced SM. The Company is developing BLU-263, an investigational, orally available KIT inhibitor, for the treatment of non-advanced SM and other mast cell disorders.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Blueprint Medicines Corp revenues decreased 77% to $180.1M. Net loss totaled $644.1M vs. income of $313.9M. Revenues reflect Collaboration revenue decrease of 84% to $122.4M. Net loss reflects Other Research and development increase of 91% to $561.4M (expense), Selling/General/Admin Expense increase of 24% to $143.3M (expense), Stock-based Compensation in SGA increase of 24% to $52M (expense).

Industry:

Biotechnology & Medical Research (NEC)

45 Sidney Street
CAMBRIDGE
MASSACHUSETTS 02139
US

Income Statement

Annual
Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024